10.25384/SAGE.6159617.v1
Orit Cohen-Barak
Orit
Cohen-Barak
Sivan Weiss
Sivan
Weiss
Michele Rasamoelisolo
Michele
Rasamoelisolo
Nicola Faulhaber
Nicola
Faulhaber
Paul P Yeung
Paul P
Yeung
Pippa S Loupe
Pippa S
Loupe
Esther Yoon
Esther
Yoon
Mohit D Gandhi
Mohit D
Gandhi
Ofer Spiegelstein
Ofer
Spiegelstein
Ernesto Aycardi
Ernesto
Aycardi
Supplementary Figure 1 bottom panel -Supplemental material for A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects
SAGE Journals
2018
Calcitonin-gene-related peptide
CGRP
fremanezumab
preventive migraine treatments
TEV-48125
2018-04-18 12:00:00
Figure
https://sage.figshare.com/articles/figure/Supplementary_Figure_1_bottom_panel_-Supplemental_material_for_A_phase_1_study_to_assess_the_pharmacokinetics_safety_and_tolerability_of_fremanezumab_doses_225_mg_675_mg_and_900_mg_in_Japanese_and_Caucasian_healthy_subjects/6159617
<p>Supplemental material, Supplementary Figure 1 bottom panel for A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects by Orit Cohen-Barak, Sivan Weiss, Michele Rasamoelisolo, Nicola Faulhaber, Paul P Yeung, Pippa S Loupe, Esther Yoon, Mohit D Gandhi, Ofer Spiegelstein and Ernesto Aycardi in Cephalalgia</p>